Absci
potential best in class a designed using generative designed a program designed to achieve superior therapeutic properties over clinical competitors designed | Absci
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
14 of 22
Related slides by other companies
Hillevax
IPO
April 2022
we believe that clinical data have substantially risked the program key clinical accomplishments adjuvant selection safety tolerability profile | Hillevax
MaxCyte
Investor Presentation
May 2023
leading partner for complex cellular engineering | MaxCyte
Kymera
Investor Presentation
August 2023
part summary | Kymera
MindMed
Investor Presentation
June 2023
preclinical data indicate potential enhanced benefit risk profile | MindMed
Other recent decks by Absci
See all presentations (12 decks)
Investor Presentation
December 2023
Investor Presentation
October 2023
Investor Presentation
October 2023
Investor Presentation
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io